Cancer Biotech’s ‘A Ray’ of Hope

As promised, a continuation of yesterday’s reader feedback…

“The Fed raising rates and decreasing the balance sheet is harming the economy but those are just two reasons for the slowing economy.

“The exploding U.S. government debt plays a role. The deportation of people has an impact; reducing… immigration decreases [economic] activity. Tariffs have a huge impact and corporate tax incentives will have long-term repercussions.

“Businesses building and upgrading facilities (made possible by tax cuts) in the U.S. will certainly be more automated than existing factories which will lead to fewer jobs. Whether those jobs mean lost wages overseas or here in the U.S., it will create unemployment.

“[These factors] will trigger the next financial crisis.

“The president is directly responsible; he even brags about it. The problem is [Trump] has no idea his policies will collapse the U.S. economy.”

Agree with any or all of what the reader has to say?

Your Rundown for Thursday, March 7, 2019:

A Ray of Hope

Array BioPharma (ARRY) is a Boulder-based company that “focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific,” according to Array’s website.

Currently, the company has two drugs on the market to treat metastatic melanoma in patients with a particular gene mutation; before the development of these drugs, there was no treatment for this patient population.

Array also has a drug in third-stage clinical trials to treat patients with metastatic colorectal cancer — also for patients with a similar gene mutation.

What called our attention to this Nasdaq-listed stock is shares escalated in the month of February, up 22.9%.


Things we like about ARRY…

  • U.S. sales of Array’s two melanoma drugs totaled $22.7 million for the second quarter of fiscal year 2019 versus first-quarter sales of $14 million.
  • Array’s value has surged 62.95% year to date (YTD) against a rise of 29.29% in 12 month’s time.
  • ARRY has a trailing 3-year beta of 1.49, offering a potential higher rate of return (admittedly, that comes with some risk).
  • The average consensus rating on ARRY is 1.6; if 5 equals a unanimous sell rating, then analysts are calling this stock a buy.

If you can stomach some volatility, Array BioPharma might be one to add to your portfolio.

[Ed. note: A 25-year investment insider has come forward with this urgent announcement to American seniors.

We’ve prepared a short message to explain the entire time-sensitive situation…. that might add as much as $383,515 to your retirement.

You can view it today, March 7, by clicking right here.]

Market Rundown for Thurs. March 7, 2019

S&P 500 futures are up 3 points to 2,774.75.

Oil is up 62 cents per barrel to $56.84.

Gold is down $3.40 to $1,284.20.

Bitcoin is up $8.98 to $3,883.51.

Have a good day. We’ll talk tomorrow.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler